Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $30 and keeps a Buy rating on the shares after the FDA approved an update to the labeling for Filspari. The FDA agreed to reduce the frequency of liver function monitoring from monthly to every three months starting at treatment initiation, and to remove the pregnancy monitoring requirement, the analyst tells investors in a research note. The firm sees the move as creating a competitive advantage for Filspari.